Despite these constraints, the investigators concluded that the results reinforce current perinatal HIV treatment ...
Switching to a long-acting cabotegravir/rilpivirine antiretroviral regimen may be safe for patients with HIV who have prior hepatitis B virus exposure, a real-world study shows.
Switching to long-acting CAB/RPV was not linked to HBV reactivation or incident infection and may be a safe therapeutic option for most patients with HIV.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results